0      0

eSymposia | Antibodies and Vaccines as Drugs for COVID-19


ek31-esym-session-muik-alexander - Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine


Jan 14, 2021 9:45am ‐ Jan 14, 2021 10:00am

Speaker(s):

You must be logged in and own this session in order to post comments.

Leo OzurumbaDwight
1/13/21 9:34 am

Good day sir. Please how did your team take care of ADE antibody dependent enhancement, to ensure it is negated as effect from this vaccine ? Was BNT162b2 mRNA designed to take care of mutations that led to Sarscov-2 mutants such as B.1.1.7 UK mutant and 501.V2 mutant ? The key muttion in 501.V2 South African mutant presents a key mutation in spikenororein called E484K. This mutation is reputed to reduce antibody recognition.This enhances progression of diseases, create windows for possible rapid spread and can be a source of concern to developed vaccines. Has this BNT162b2 mRNA been designed to neutralize this problem and shrug it off to enhance long lasting protection ? Or do we have a challenge in our hands that requires us LL to wait for some months and see how these current 3 vaccines from Pfizer-BioN Tech, Moderna and Astra Zeneca-Oxford University cope ? Good luck, thank you and I comments your efforts at BioN Tech. Your efforts at BioN Tech is commendble. Warm regards sir. Thank you. Leo Ozurumba-Dwight. Walden University MN US

Print Certificate
Completed on: token-completed_on
Print Transcript
Please select the appropriate credit type:
/
test_id: 
credits: 
completed on: 
rendered in: 
* - Indicates answer is required.
token-content

token-speaker-name
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
/
/
token-index
token-content
token-index
token-content